Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Senators press Mylan Labs over ‘outrageous’ EpiPen pricing
Senators press Mylan Labs over ‘outrageous’ EpiPen pricing
Move over, Martin Shkreli.
NICE knocks Bayer's Nexavar as CDF review continues
NICE knocks Bayer's Nexavar as CDF review continues
Add Bayer to the list of drugmakers that are feeling the heat from NICE’s Cancer Drugs Fund takeover.
Pfizer to Buy Cancer Drug Maker in $14 Billion Deal
Pfizer to Buy Cancer Drug Maker in $14 Billion Deal
Medivation, which makes the big-selling drug Xtandi to treat prostate cancer, has finally found its buyer in a fellow American drug maker, Pfizer.
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
AstraZeneca and Eli Lilly and Company (Lilly) have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3...
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
NEW YORK--(BUSINESS WIRE) -- Pfizer Inc.
With FDA delay, Sanofi loses head start in diabetes combo-med rivalry with Novo
With FDA delay, Sanofi loses head start in diabetes combo-med rivalry with Novo
Sanofi spent $245 million on a priority review voucher to beat Novo Nordisk to market with a diabetes med pairing a basal insulin with a GLP-1.
Compound from marine sponge may reduce pancreatic tumor size
Compound from marine sponge may reduce pancreatic tumor size
BOCA RATON, Fla.
Pfizer boosts cancer drug roster with $14 billion Medivation deal
Pfizer boosts cancer drug roster with $14 billion Medivation deal
Pfizer Inc (PFE.
Approval of tenecteplase for stroke in India misguided, says expert
Approval of tenecteplase for stroke in India misguided, says expert
Plans by Indian drugmaker Gennova to launch its generic clot-buster tenecteplase as a treatment for stroke in India are "incomprehensible," according to a leading stroke expert.
The government agency in charge of approving drugs gets a surprising amount of money from the companies that make them
The government agency in charge of approving drugs gets a surprising amount of money from the companies that make them
Getting a drug all the way to approval is no easy feat — for pharmaceutical companies or for regulators.
Miami Beach Zika Cases May Prompt Call to Avoid City
Miami Beach Zika Cases May Prompt Call to Avoid City
MIAMI BEACH — A cluster of Zika cases most likely transmitted by local mosquitoes has been identified in Miami Beach, and federal and state officials are considering whether to advise pregnant women...
NHS patients missing out on new cancer treatments available in other countries, report finds
NHS patients missing out on new cancer treatments available in other countries, report finds
NHS patients are missing out on new cancer treatments because health chiefs are failing to negotiate better prices for drugs, two leading cancer charities have warned.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand